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Abstract
Objectives: Chronic kidney disease is frequent in pa-
tients after orthotopic liver transplantation (OLT) and
has impact on survival. Patients receiving calcineurin
inhibitors (CNI) are at increased risk to develop im-
paired renal function. Early CNI reduction and con-
comitant use of mycophenolat mofetil (MMF) has
been shown to improve renal function.
Methods: The aim of this trial was to compare dose-re-
duced CNI/MMF versus CNI-free MMF/prednisone-
based treatment in stable patients after OLT with re-
spect to glomerular filtration rate (GFR). 21 patients
[GFR 44.9 ± 9.9 mL/min/1.73m2 measured by 99m-
Tc-DTPA-clearance, serum creatinine (SCr) 1.5 ± 0.42
mg/dL] were randomized either to exchange CNI for
10 mg prednisone (group 1; n = 8) or to receive CNI
at 25% of the initial dose (group 2; n = 13) each in
combination with 1000 mg MMF b.i.d.
Results: At month 12 mean SCr (-0.3 ± 0.4 mg/dL, p
= 0.031) and GFR improved (8.6 ± 13.1 mL/min/
1.73m2, p = 0.015) in group 2 but remained un-
changed in group 1. Main side effects were gastroin-
stestinal symptoms (14.3%) and infections (4.8%).
Two biopsy proven, steroid-responsive rejections oc-
curred. In group 1 mean diastolic blood pressure (BP)
increased by 11 ± 22 mmHg (p = 0.03).
Conclusions: Reduced dose CNI in combination with
MMF but not CNI-free-immunosuppression leads to
improvement of GFR in patients with moderately ele-
vated SCr levels after OLT. Addition of steroids re-
sulted in increased diastolic blood pressure presum-
ably counterbalancing the benefits of CNI withdrawal
on renal function.
Key words: calcineurin inhibitor, GFR, impaired renal
function, liver transplantation, mycophenolate mofetil
Abbreviations: CNI, calcineurin inhibitor; GFR, glo-
merular filtration rate; eGFR, estimated GFR; MMF,
mycophenolate mofetil; OLT, orthotopic liver trans-
plantation; SE, side effects; SCr, serum creatinine
INTRODUCTION
Liver transplant recipients are the second most fre-
quent group of patients, who develop chronic renal
failure among all recipients of solid organ transplanta-
tion [1]. Up to 18% of patients after OLT have been
shown to suffer from end stage renal disease (ESRD)
within 10 years after engraftment [2]. Apart from pre-
operative GFR, diabetes and chronic hepatitis C infec-
tion [1, 3], the use of calcineurin inhibitor (CNI)
based immunosuppression has been shown to put the
patient at particular risk to develop chronic kidney dis-
ease [4].
Therefore, both CNI-sparing and CNI free regi-
mens should offer an opportunity to treat liver trans-
plant recipients with impaired renal function. Whereas
CNI reduction with concomitant use of mycopheno-
late mofetil (MMF) has been demonstrated as an suc-
cessful and safe option [6-13], MMF monotherapy was
complicated by a high frequency of rejection episodes
[5, 14]. Alternatively CNI withdrawal has been studied
in combination with conversion to mTor inhibitors.
However, results in such studies are controversial [15,
16]. Finally it remains unclear, whether the high rate of
rejection episodes can be prevented when MMF
monotherapy is combined with steroids.
We performed a single center prospective random-
ized pilot trial to compare a dose reduced CNI/MMF-
versus a MMF/prednisone treatment in patients after
liver transplantation with moderately impaired renal
function.
PATIENTS AND METHODS
PATIENT RECRUITMENT
Patients were screened for renal impairment by 99m-
Tc-DTPA-clearance following the method of Russell
et al. [17] and included if GFR was below 70 mL/
min/1.73m2. Additional inclusion criteria consisted of
age greater than 18 years and CNI-toxicity as main
cause of impaired renal function by excluding other
factors such as relevant proteinuria (>1 g/24 h),
hematuria or diabetes mellitus. Exclusion criteria com-
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nine (SCr) > 5 mg/dL, (re-) infection with hepatitis B
(HBs-antigen positive), rejection episodes during the
previous 12 months, CMV-infection during the previ-
ous 6 months, contraindications for the use of corti-
costeroids or MMF, pregnancy or breast-feeding, un-
willingness in pre-menopausal women to take contra-
ceptives for the duration of the study, active gastric ul-
cer disease, malignancy, hemoglobin < 10 g/dL, total
leucocyte counts < 3.5 G/L and platelet counts < 70
G/L.
The study protocol was approved by the local ethics
committee in accordance with the principles of the
declaration of Helsinki.
STUDY PROTOCOL
Patients were randomized either to completely discon-
tinue CNI and to add 10 mg prednisone instead
(group 1) or to reduce the CNI to 25% of the initial
dosage without any additional corticosteroids (group
2). Each patient received 1000 mg MMF b.i.d..
CNI was tapered stepwise over 8 weeks after target
MMF dose was achieved. To ensure equal renal func-
tion starting levels patients were first stratified with
respect to serum creatinine above and below 1.4
mg/dL and than randomly allocated to the study
groups at a 1:1 ratio using randomization blocks of
five subjects.
For every suspected rejection, histological confir-
mation was obtained. Patients with biopsy proven re-
jection (BPR) were judged as treatment failure and
withdrawn from the study.
FOLLOW UP
After study inclusion, patients were monitored in
weekly intervals for the first 14 weeks. At each visit
blood counts, liver functions tests and ciclosporine- or
tacrolimus 12-h serum concentrations were measured
and any side effects were recorded. At inclusion as
well as after months 6 and 12 serum creatinine (Scr)
and 99m-Tc-DTPA-clearance were measured.
ANALYSIS OF THE DATA
The study was evaluated on an intent-to treat (ITT-)
basis. Results are expressed as arithmetic means ± SD.
Statistical analysis was performed using the StatView
5.0TM Software (Version for Windows; SAS Institute
Inc., Cary, NC, USA). Differences between the groups
were analyzed by Mann-Whitney-Test and differences
of paired values by Wilcoxon-Rank-Test. p-values <
0.05 were considered significant.
RESULTS
BASELINE CHARACTERISTICS
Between May 2003 and May 2005 twenty-one patients
with a GFR <70 mL/min/1.73 m2 were randomized
into the treatment groups (group 1: n = 8; group 2: n
= 13). Patient characteristics and immunosuppressive
medication at the time of study inclusion are given in
Table 1. There were no statistical significant differ-
ences noted between both groups regarding age, time
since engraftment and renal function as determined by
SCr and 99Tc-DTPA-clearance.
CNI through levels at baseline were 9.1 ± 1.4
ng/ml (tacrolimus) and 83.9 ± 14.5 ng/mL (ci-
closporin) in group 1 and 9.1 ± 1.7 ng/mL and 81.7 ±
12.4 ng/mL in group 2, respectively. In group 2 CNI
levels were reduced to 3.4 ± 1.9 ng/mL (tacrolimus)
and 26.7 ± 3.5 (ciclosporin) at month 6 and 3.7 ± 1.9
ng/mL and 32 ± 5.7 ng/mL at month 12, respectively.
EFFECT ON RENAL FUNCTION
SCr levels and GFRs are summarized in Figures 1 and
2, respectively. At month 6, none of the groups re-
vealed a significant change of SCr and GFR as com-
pared to baseline. After 12 months, however, a statisti-
cally significant decrease of mean SCr (-0.3 ± 0.4
mg/dL, p = 0.031) and a corresponding rise in mean
GFR (8.6 ± 13.1 mL/min/1.73m2, p = 0.015) could
be recorded in patients randomized into group 2,
whereas no significant improvement of GFR was not-
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Table 1. Patients baseline characteristics at study inclusion. Values are given as mean ± SD.
All (n = 21) Group 1 (n = 8) Group 2 (n = 13) P =
Age (years) 47.9 ± 11.3 47.3 ± 11.8 48.4 ± 11.5 0.71
Male/female 12/9 4/4 8/5
Time after engraftment (months) 6 ± 3.1 6.3 ± 3.4 5.5 ± 2.8 0.71
Baseline creatinine (mg/dL) 1.5 ± 0.42 1.57 ± 0.46 1.45 ± 0.41 0.64
Baseline GFR (mL/min) 44.9 ± 9.9 42.2 ± 10.2 46.5 ± 9.8 0.33
Immunosuppression at the time of inclusion
Ciclosporin/through level (ng/ml) N = 10 N = 5 N = 5 0.72
(83.9 ± 14.5) (85.6 ± 17.6) (81.7 ± 12.4)
Tacrolimus/ through level (ng/ml) N = 11 N = 3 N = 8 0.73
(9.1 ± 1.7) (9.2 ± 2.4) (9.1 ± 1.4)
Prednisone frequency/ dose (mg/day) N = 7 N = 5 N = 2
(4.4 ± 1.5) (5 ± 0) (3 ± 2.8)
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mg/dL and 1.5 ± 17.7 mL/min/1.73m2, respectively).
COURSE OF BLOOD PRESSURE AND BLOOD LIPID
LEVELS
In the CNI-free steroid containing treatment arm a
significant rise in mean diastolic blood pressure was
recorded from 73.2 ± 15.1 mmHg at study inclusion
to 83.6 ± 10.3 mmHg at month 12 (11 ± 22 mmHg; p
= 0.03), whereas diastolic and systolic blood pressure
remained unchanged in patients receiving CNI at a re-
duced dosage (Fig. 3). At baseline, 7 patients received
antihypertensive medication, which was intensified in
2 patients during the course of the study (one in each
group). One additional patient from group 1 had to be
started on antihypertensive treatment. In contrast to
blood pressure, mean levels of cholesterin and triglyc-
erides remained unchanged after conversion to the
study medication and during follow up. At baseline a
single patient in group 2 received a statin owing to the
need for highly active antiretroviral therapy to treat co-
existing HIV infection. In this individual, a dramatic
decrease of triglycerides was noted after conversion to
the CNI-free regimen. One more patient (group 2)
had to be started on a lipid-lowering medication dur-
ing the course of the study.
SIDE EFFECTS AND REJECTION EPISODE
Observed side effects (SE) consisted of gastrointesti-
nal problems (abdominal discomfort and diarrhea)
(14.3%), genital herpes simplex infection (4.8%), ob-
servation of pleural effusion and ascites of unknown
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Table 2. Observed side effects after conversion to MMF.
All (n =) Group 1 (n =) Group 2 (n =) Discontinuation
Gastroinestinal symptoms
(abdominal discomfort, diarrhea) 32 1 2
Herpes simplex infection 10 1 0
Ascites/pleural effusion 10 1 0
Myoclonia 10 1 1
Rejection (BPR) 21 1 2
Fig. 1. SCr levels measured after engraftment, at
study inclusion and months 6 and 12 after conver-
sion to MMF therapy. Data are given as box plots,
where the limits of the boxes indicate the 25th and
75th percentiles and the lines inside the boxes indi-
cate the 50th (median) percentile. The whiskers indi-
cate the 10th and 90th percentiles.
Fig. 2. GFR measured by 99m-Tc-DTPA-Clearance
at study inclusion and months 6 and 12 after conver-
sion to MMF therapy. Data are given as box plots,
where the limits of the boxes indicate the 25th and
75th percentiles and the lines inside the boxes indi-
cate the 50th (median) percentile. The whiskers indi-
cate the 10th and 90th percentiles.
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One patient experienced acute renal failure with the
onset of heavy diarrhea and was discontinued from
the study. Under treatment with intravenous fluids re-
nal function could be restored to the previous level.
Allocation of the side effects to both treatment
groups and SE-related discontinuation of MMF thera-
py are depicted in Table 2. In the patient with poly-
serositis, symptoms re-occurred 17 months after dis-
continuation of MMF application. There was no sig-
nificant change in serum ALT levels during the study
period (Fig. 4). BPR occurred in 2 patients. The first
patient, allocated to treatment group 1, underwent liv-
er biopsy because of an increase of liver function tests
at week 32. She was re-placed on tacrolimus based im-
munosuppression after receipt of the pathology re-
port. The second patient underwent liver biopsy be-
cause of the appearance of unclear polyserositis in the
absence of increased liver function tests. Both rejec-
tions were considered as mild by the pathologist and
responded well to steroid pulse therapy.
Altogether study medication had to be terminated
in 5 patients (23.8%). Discontinuation of the study
medication occurred due to side effects or rejection
(GI-side effects n = 2, myoclonia n = 1, BPR n = 2).
One additional patient withdrew consent shortly after
study inclusion due to the discontinuation of contra-
ceptive medication.
None of the patients required dose adjustments for
low leukocyte, platelet counts or anemia and none de-
veloped diabetes.
DISCUSSION
Here, we report the results of a pilot trial on CNI-free
versus a CNI reduced immunosuppression under the
concomitant use of MMF in liver transplant recipients
with impaired renal function, applying 99m-Tc-DTPA
clearance – the gold standard method - to measure
GFR. We found, that conversion to MMF in combina-
tion with CNI-dose reduction was able to significantly
improve GFR, whereas the CNI-free regimen in com-
bination with steroids did not ameliorate renal func-
tion.
Previous studies have already demonstrated a posi-
tive effect of CNI-dose reduction on renal function in
liver transplant recipients with chronic kidney disease.
The following various approaches have been studied:
de novo immunosuppression with MMF combined
with delayed introduction of CNI’s [7-9], reduced
dose CNIs either de novo [10] or reduction after
more than one year after engraftment [11-14]. Howev-
er, in these studies assessment of renal function had
been based on indirect methods such as serum creati-
nine [5], creatinine clearance [11-13] or creatinine
based estimated GFR (eGFR) [7-9]. In contrast, we
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Fig. 3. Systolic and diastolic BP at baseline and 12
months after inclusion into the study. Data are given
as box plots, where the limits of the boxes indicate
the 25th and 75th percentiles and the lines inside the
boxes indicate the 50th (median) percentile. The
whiskers indicate the 10th and 90th percentiles.
Fig. 4. ALT levels measured at study entry and at
months 6 and 12 after conversion to MMF therapy.
Data are given as box plots, where the limits of the
boxes indicate the 25th and 75th percentiles and the
lines inside the boxes indicate the 50th (median) per-
centile. The whiskers indicate the 10th and 90th per-
centiles.
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standard method to measure glomerular function - to
evaluate the course of renal function after conversion,
since it has meanwhile been well established that
serum creatinine and creatinine based equations, e.g.
MDRD, only insufficiently reflect true GFR [18, 19].
In contrast to the work of Schlitt, Reich and Créput
[5, 11, 14], CNI-free immunosuppression did not re-
veal any improvement of renal function in our pa-
tients. However, since we used an ITT analysis, the
number of drop-outs may have influenced our assess-
ment of outcomes.
In our study, CNI-free immunosuppression com-
prised MMF in combination with corticosteroids,
which had been chosen, because a high number of re-
jections had been reported in patients with MMF
monotherapy. Although only a low dose of 10 mg
prednisone was administered, this type of treatment
was associated with an increment of 11 mmHg in di-
astolic blood pressure. This unexpected effect may
have counterbalanced the potentially positive effects
of CNI withdrawal in our patients in group 1. On the
other hand, both MMF in combination with reduced
dose CNI and MMF in combination with corticos-
teroids proved to be relatively safe, taking into account
that acute rejection occurred in only 10% (2/21) of
patients. Of note, all rejection episodes responded
well to corticosteroid pulse therapy, so that normal he-
patic function was restored in all patients with rejec-
tion. Both rejection episodes occurred in a “stable
phase” of immunsuppression 4.6 and 7.5 months after
conversion, so that the causal relationship to the treat-
ment protocol remains unclear. In our study the fre-
quency of BPR was similar to that reported by Reich
et al. (9-14%) but higher than in the trials of Pageaux
and Creput (0%) [11-13].
As expected, gastrointestinal intolerance was the
most frequent side effect, which required treatment
discontinuation in 2 of 3 patients with this complica-
tion. Otherwise, the spectrum of side effects was simi-
lar to other studies. Herpes infection is a complication
which had already been previously attributed to MMF
treatment [20]. In contrast, myoclonia, which was ob-
served in a single patient of group 2 has not yet been
reported under MMF medication. Finally, polyserositis
which was observed also in a patient must most likely
not be attributed to MMF medication, because the
syndrome re-occurred 17 months after MMF had been
discontinued.
This study had been planned as a pilot trial to pro-
vide data for a larger multicentre trial. Thus the low
number of patients and the single centre design may
limit interpretation of our results. Nevertheless, we
obtained a clear result not favouring CNI-free im-
munosuppression in liver transplant recipients with
impaired renal function. Of note this result is based
on direct measurement of GFR with a gold standard
method rather than indirect assessments of renal
function by serum creatinine or eGFR which may be
invalid in patients after liver transplantation [18, 19] or
with impaired liver function.
Thus, the obligate use of corticosteroids with their
potentially hypertensive effect cannot be generally rec-
ommended in a CNI-free regimen of MMF-based im-
munosuppression. In addition, our trial adds evidence
to the existing data using a GFR gold standard meaes-
urement, that CNI-reduction in combination with
MMF is a safe and effective method to treat liver
transplant recipients with an impairment of renal
function.
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